Shiells, HelenSchelter, Bjoern O.Bentham, PeterBaddeley, Thomas C.Rubino, Christopher M.Ganesan, HarishHammel, JeffreyVuksanovic, VesnaStaff, Roger T.Murray, Alison D.Bracoud, LucWischik, Damon J.Riedel, GernotGauthier, SergeJia, JianpingMoebius, Hans J.Hardlund, JiriKipps, Christopher M.Kook, KarinStorey, John M. D.Harrington, Charles R.Wischik, Claude M.2020-06-022020-06-022020-05-19Shiells, H, Schelter, B O, Bentham, P, Baddeley, T C, Rubino, C M, Ganesan, H, Hammel, J, Vuksanovic, V, Staff, R T, Murray, A D, Bracoud, L, Wischik, D J, Riedel, G, Gauthier, S, Jia, J, Moebius, H J, Hardlund, J, Kipps, C M, Kook, K, Storey, J M D, Harrington, C R & Wischik, C M 2020, 'Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia', Journal of Alzheimer's Disease, vol. 75, no. 2, pp. 501-519. https://doi.org/10.3233/JAD-1911731387-2877ORCID: /0000-0002-5261-5467/work/75444735ORCID: /0000-0003-4915-4847/work/76976609ORCID: /0000-0003-2250-3920/work/173415894https://hdl.handle.net/2164/14427Funding The study was sponsored by TauRx Therapeutics (Singapore). Acknowledgments We gratefully acknowledge study investigators and the generosity of study participants.19474195engSDG 3 - Good Health and Well-beingHydromethylthionineLeucomethylthioniniumBehavioural variant frontotemporal dementiaClinical trialsTau proteinTDP-43leucomethylthioniniumhydromethylthionineBehavioral variant frontotemporal dementiaclinical trialstau proteinMETHYLENE-BLUELOBAR DEGENERATIONALZHEIMERS-DISEASESEROTONIN TOXICITYPICK BODIESAGGREGATION INHIBITOR THERAPYDOUBLE-BLINDTAU-AGGREGATIONDIAGNOSTIC-CRITERIAPROGRESSIONRC0321 Neuroscience. Biological psychiatry. NeuropsychiatryGeriatrics and GerontologyPsychiatry and Mental healthClinical PsychologyGeneral NeuroscienceSupplementary DataRC0321Journal article10.3233/JAD-191173http://www.scopus.com/inward/record.url?scp=85085265745&partnerID=8YFLogxK752